Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 49.25%
March 31, 2026 50.70%
December 31, 2025 47.21%
September 30, 2025 47.99%
June 30, 2025 45.35%
March 31, 2025 48.63%
December 31, 2024 45.20%
September 30, 2024 45.44%
June 30, 2024 46.17%
March 31, 2024 44.82%
December 31, 2023 46.46%
September 30, 2023 36.59%
June 30, 2023 45.34%
March 31, 2023 50.51%
December 31, 2022 47.52%
September 30, 2022 53.72%
June 30, 2022 55.53%
March 31, 2022 57.16%
December 31, 2021 53.10%
September 30, 2021 54.60%
June 30, 2021 58.79%
March 31, 2021 55.68%
December 31, 2020 51.70%
September 30, 2020 57.87%
June 30, 2020 57.85%
Date Value
March 31, 2020 57.97%
December 31, 2019 51.25%
September 30, 2019 49.08%
June 30, 2019 52.26%
March 31, 2019 51.42%
December 31, 2018 50.92%
September 30, 2018 49.95%
June 30, 2018 50.30%
March 31, 2018 50.19%
December 31, 2017 47.43%
September 30, 2017 39.92%
June 30, 2017 54.85%
March 31, 2017 51.93%
December 31, 2016 52.49%
September 30, 2016 52.21%
June 30, 2016 54.83%
March 31, 2016 54.30%
December 31, 2015 50.83%
September 30, 2015 55.36%
June 30, 2015 58.12%
March 31, 2015 61.22%
December 31, 2014 50.69%
September 30, 2014 51.79%
June 30, 2014 55.03%
March 31, 2014 59.68%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
BioLife Solutions, Inc. 63.69%
Anika Therapeutics, Inc. 65.15%
Danaher Corp. 57.64%
Precigen, Inc. 94.32%
Liquidia Corp. 93.10%